ENPP2 and pulmonary fibrosis: Notably, from a therapeutic standpoint, the recent entry and the so far very promising results of the first-in-class ATX inhibitor GLPG1690 (Figure 1) [23] in advanced clinical trials against idiopathic pulmonary fibrosis lends support to the viability and validity of this approach, bringing it to the forefront of drug discovery efforts [23,27].